That visit is what makes sure the formula is right for you, that there's nothing that rules it out, and that your treatment is properly prescribed and documented
On April 30, 2026, FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list
GLP-1s were associated with lower risk of new substance use disorder diagnoses Across alcohol, cannabis, cocaine, nicotine, opioids, and other drug categories, people who started a GLP-1 medication were less likely to receive a new substance use disorder diagnosis over the following 3 years relative to those who started the comparison diabetes medication, sodium-glucose cotransporter-2 inhibitor
Available from: Accessed 1 Mar 2023 Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications